After taking shareholders on something of a roller coaster ride last year, Seattle Genetics CEO Clay Siegall rewarded himself with a compensation package that swelled to more than twice the size of his financial reward for 2017.
Adding significantly to his columns on stock awards and options, Siegall’s compensation soared to $18.1 million last year, up from $8.6 million in 2017 and the $9.5 million package he garnered the year before that. That put his compensation at a multiple of 91 over the average salary at Seattle Genetics.
Merck vet Roger Dansey, the CMO who joined the company in May, rang up close to $10 million in compensation. CFO Todd Simpson, meanwhile, bagged $4.4 million in compensation, up from $3 million.
Seattle Genetics’ stock gained overall over the course of the year as the company captured its 5th OK for Adcetris, beefed up the pipeline and pushed its second armed antibody — enfortumab vedotin — to the FDA finish line.
Those income numbers put Siegall in the middle of the pack of compensation totals we’ve been tracking, with his packet adding up to a bigger figure than Eli Lilly CEO Dave Ricks ($17.2 million), or AstraZeneca chief Pascal Soriot ($14.8 million) — two companies which have a market cap way ahead of $SGEN. It’s also way above what Emma Walmsley garnered, still at the bottom of the chart with $7.7 million in compensation.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription